Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10327061 | 1.00 | HTR6 (1.00) | HTR6ADRA2AHTR2C | |
| SCHEMBL10326475 | 0.95 | HTR6 (0.91) | HTR6ADRA2AHTR2C | |
| SCHEMBL2899941 | 0.95 | HTR6 (0.91) | HTR6ADRA2AHTR2C | |
| SCHEMBL10327112 | 0.91 | HTR6 (0.83) | HTR6ADRA2AHTR2C | |
| SCHEMBL10327167 | 0.86 | HTR6 (0.75) | HTR6ADRA2AHTR2C | |
| SCHEMBL2903406 | 0.80 | HTR6 (1.00) | HTR6ADRA2AHTR2C | |
| SCHEMBL10326497 | 0.80 | HTR6 (1.00) | HTR6ADRA2AHTR2C | |
| SCHEMBL14538817 | 0.79 | HTR6 (0.66) | HTR6ADRA2AHTR2C | |
| SCHEMBL2906880 | 0.79 | HTR6 (1.00) | HTR6ADRA2AHTR2C | |
| SCHEMBL2905307 | 0.75 | HTR6 (1.00) | HTR6ADRA2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | claimed |
| EP-2202222-A2 | Indene derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-06-30 | — | — | EP | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | claimed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | disclosed |
| EP-2202222-A2 | Indene derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | HTR6 1/4885ADRA2A 65/4885HTR2C 5/4885 |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, HTR1A | HTR6 1/4885ADRA2A 25/4885HTR2C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.